Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Thyroid Neoplasms 4Hypothyroidism 3Medulloblastoma 2Breast Neoplasms 2Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Goiter 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Brain Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Cyclophosphamide 35Temozolomide 33Filgrastim 26Etoposide 26Carboplatin 25Vincristine 22Cisplatin 22Radiotherapy 20Magnetic Resonance Spectroscopy 18Thiotepa 14Irinotecan 13Granulocyte Colony-Stimulating Factor 12Peripheral Blood Stem Cell Transplantation 11Lomustine 11Specimen Handling 9Radiation 9Melphalan 9etoposide phosphate 8Topotecan 8Methotrexate 8X-Rays 7Platinum 7Phantoms, Imaging 7sonidegib 6Biopsy 61,2-diaminocyclohexaneplatinum II citrate 6sargramostim 5palbociclib 5Nuclear Medicine Department, Hospital 5HhAntag691 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Medulloblastoma × Triiodothyronine × Clear all
NCT07346157 2026-06-01

PNOC044

University of California, San Francisco

Phase 1/2 Not yet recruiting
69 enrolled
CNS

Medulloblastoma

NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡